# Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

Source: https://onco.cc/trials/nct05079230/  
OnCo record `nct05079230` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Magrolimab, Venetoclax and Azacitidine in Acute myeloid leukaemia, run by Gilead Sciences, recorded as terminated on the registry.

## Summary

Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia is a phase 3 interventional study registered as NCT05079230 by Gilead Sciences, with 378 participants recorded, started 2022-07-07 and due to reach its primary completion in 2024-04-11. Interventions recorded: Magrolimab, Venetoclax, Azacitidine, Placebo. Conditions recorded: Acute Myeloid Leukemia.

Linked to the drug Magrolimab because the registry names it among its interventions and Acute myeloid leukaemia among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05079230
- Phase: 3
- Setting: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
- Sponsor: Gilead Sciences
- Enrolled: 378

## Sources

- ClinicalTrials.gov NCT05079230: https://clinicaltrials.gov/study/NCT05079230

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [Azacitidine](https://onco.cc/drugs/azacitidine/), [Magrolimab](https://onco.cc/drugs/magrolimab/), [Venetoclax](https://onco.cc/drugs/venetoclax/)
- companies: [Gilead Sciences (incl. Kite)](https://onco.cc/companies/gilead/)

---
JSON: https://onco.cc/api/v1/entities/nct05079230.json